This study investigates the potential use of raloxifene, a selective estrogen receptor modulator (SERM), in treating cancers beyond breast carcinoma. The research highlights raloxifene's effects on tumor growth in various systemic malignancies, including endometrial, ovarian, and prostate cancers. The study concludes that raloxifene may provide a therapeutic benefit by inhibiting
